Premium
Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma
Author(s) -
Robertson John M.,
Shewach Donna S.,
Lawrence Theodore S.
Publication year - 1996
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19960801)78:3<674::aid-cncr48>3.0.co;2-t
Subject(s) - medicine , gemcitabine , radiation therapy , pancreatic cancer , oncology , cancer research , chemotherapy , cytotoxicity , radiobiology , pancreatic carcinoma , radiosensitizer , cancer , mechanism (biology) , in vitro , biology , biochemistry , philosophy , epistemology
The use of radiation therapy combined with 5‐fluorouracil (5‐FU) in the treatment of pancreatic cancer has been well established. It has been hypothesized that any benefit from combined 5‐FU and radiation has been due to radiosensitization. Improved therapy could result from a better understanding of the mechanism of radiosensitization and the development of compounds capable of providing better radiosensitization. This article reviews preclinical findings on the mechanism of cytotoxicity and radiosensitization for 5‐FU, fluorodeoxyuridine, thymidine analogs, and gemcitabine (2′,2′‐difluorodeoxycytidine) and discusses the clinical implications of these findings. Cancer 1996;78:674‐9.